| Value | ₹7.33 Cr |
|---|---|
| Execution period | Tentatively completed by 31 March 2027 |
BSE filing, NSE: SMT. Summary written from the filing by ALFA Finder's alert engine.
Sahajanand Medical Technologies Ltd: key numbers
- Share price
- ₹487.75
- Market cap
- ₹4,958 Cr
- Revenue (annual)
- ₹1,210 Cr
- Net profit (annual)
- ₹65.28 Cr
- Promoter holding
- 36.20%
- FII holding
- 35.09%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sahajanand Medical Technologies Ltd
All →Sahajanand Medical Technologies Earnings Call Transcript: Key Takeaways
Record Q2 FY27: revenue up 24.7% to about ₹373 Cr, EBITDA up 36.6%, margin 17.6%. Reported H1 PAT up only 7.5% due to a prior-year one-off tax credit; ex-it about 39%. Gross margin fell 170 bps on traded-product mix.
Sahajanand Medical Technologies Investor Presentation: Key Takeaways
Q2 FY27 record: revenue ₹3,734mn (+24.7%), EBITDA ₹656mn (17.6% margin), PAT ₹265mn (+26.6%). H1 revenue ₹7,251mn (+24.9%). Growth led by Other and Shockwave-type SH products.
Sahajanand Medical Technologies Q2 FY27 Results: Net Profit ₹26.5 Cr, Up 26.8% YoY
Sahajanand Medical Technologies Ltd reported revenue from operations of ₹373.4 Cr (+24.7% YoY) and net profit of ₹26.5 Cr (+26.8% YoY) for Q2 FY27.
- Key figure
- Net profit ₹26.5 Cr · +26.8% YoY
Sahajanand Medical Technologies Legal & Regulatory
Sahajanand Medical Technologies received a GST DRC-01D recovery notice from Jharkhand tax authorities. The demand totals Rs. 34.29 lakh, which the company is contesting before appellate authorities.
- Value
- ₹0.34 Cr
Sahajanand Medical Technologies Credit Rating
CRISIL has upgraded Sahajanand Medical Technologies' long-term bank facility rating to CRISIL A-/Stable from BBB+/Stable. The upgrade reflects improved business risk, growing scale, and sustained profitability across its global stent manufacturing operations.
- Value
- ₹300.0 Cr
Sahajanand Medical Technologies Capital Structure Change
Invesco Mutual Fund schemes bought 44,20,453 Sahajanand Medical Technologies shares in the open market. Their stake rose to 5.0549%, with no transaction price disclosed.
Other acquisition announcements
All →Transpek Industry Acquisition Worth ₹41 Cr
Transpek Industry Ltd's board approved acquiring about 23 acres of leased industrial land at Tata Steel SEZ, Gopalpur, Odisha, for Rs.41.00 Crore in cash. The land will host a new chemical manufacturing unit for future expansion.
- Value
- ₹41.00 Cr
- land area
- 23.0 acres
Euro Pratik Sales Acquisition Worth ₹31.12 Cr
Euro Pratik Sales will acquire 51% control of Drashti Surfaces Private Limited for ₹31.12 Crore in cash. The acquisition expands its laminates and veneer portfolio.
- Value
- ₹31.12 Cr
- Execution
- Indicative completion within 90 days
Ashok Leyland Acquisition
Ashok Leyland announced NCLT Mumbai sanctioned the merger of its material subsidiary Hinduja Leyland Finance into NDL Ventures on November 3, 2026. NDL becomes the material listed subsidiary once the scheme takes effect.
Go Digit General Insurance Acquisition
Go Digit shareholders approved the amalgamation of Go Digit Infoworks Services into the company at an NCLT-convened meeting. No cash consideration is payable under the scheme.
Arvind SmartSpaces Acquisition
Arvind SmartSpaces will acquire 1,500 equity shares (15%) of newly incorporated Arvind Global Capability Center for Rs. 15,000 in cash. The related-party deal is expected to complete within one month.
- Execution
- Within one month from the date of Board approval
Gujarat Terce Laboratories Acquisition Worth ₹3.23 Cr
Gujarat Terce Laboratories agreed to buy its corporate office premises 'Swati18' in Ahmedabad. The purchase is for Rs 3.23 Crore, excluding taxes and charges.
- Value
- ₹3.23 Cr